February 28, 1987
The Costa Mesa, Calif., drug maker was accused Friday, in a shareholder lawsuit, of fraudulently inflating its stock price. The suit, filed in U.S. District Court in Los Angeles by a New Jersey investor, follows disclosures that ICN is the subject of three federal investigations, including one by the House Energy and Commerce Committee. An attorney for ICN declined comment on the suit. ICN's drug Virazole is being tested as a possible AIDS medication.
March 23, 1999
Costa Mesa drug maker ICN Pharmaceuticals said Monday its directors boosted the quarterly dividend to 7 cents a share from 6 cents, payable April 28 to shareholders of record April 14. The company posted a fourth-quarter loss of $218 million as it wrote off a Yugoslavian plant seized by Serbian troops. But other regions are performing well, and the company believes its drug ribavirin has a bright future as a hepatitis treatment. Last year, Schering-Plough Corp. won U.S.
March 8, 1985
The Costa Mesa drug research company said Thursday that its ribavirin drug will be tested on 21 AIDS victims at New York Hospital. The drug is used in fighting the virus believed to cause acquired immune deficiency syndrome. The company said it also is awaiting U.S. Food and Drug Administration approval for use of ribavirin in treating respiratory syncytial virus, a disease affecting about 800,000 infants, children and elderly annually in the United States.
April 7, 1992 |
Buoyed by the success of its link to an Eastern European pharmaceutical company, ICN Pharmaceuticals Inc. said Monday it earned $5.9 million, equal to 40 cents per share, last year after a 1990 loss of $22.4 million, or $1.92 a share. Sales for the drug manufacturer rose to a record $460.4 million for the year, contrasted with $272 million last year.
November 11, 1998 |
ICN Pharmaceuticals Inc., citing economic turmoil in Russia and Eastern Europe, posted a wider-than-expected loss for the third quarter. The Costa Mesa-based drug company said it lost $65 million, or 89 cents a share, compared with a profit of $34.6 million, or 61 cents a share, for the comparable period last year. Revenue fell nearly 9% to $163.0 million from $177.4 million. The company reported a pretax loss of $75 million for the recent quarter in Eastern Europe.
October 13, 1988 |
Benefiting from higher sales and the repurchase of corporate debt, ICN Pharmaceuticals Inc. reported net income of $7 million for the fiscal third quarter ended Aug. 31. It had a $756,000 profit for the same period a year ago. Third-quarter sales for the Costa Mesa firm were $41.7 million, up 31% from $31.9 million for the third quarter of fiscal 1987. For the first nine months of fiscal 1988, ICN posted net income of $17.2 million, up from $4.5 million during the same period in fiscal 1987.